ADCC Against Gastric Cancer Cells

Gastric Cancer Clinical Trial

Official title:

Evaluation of Antibody-dependent Cell Cytotoxicity (ADCC) Against Gastric Cancer Cells

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02078362
• Other study ID #: KK002
• Secondary ID: 2013/00654
• Status: Recruiting
• Phase: N/A
• First received: December 9, 2013
• Last updated: June 11, 2015
• Start date: September 2013
• Est. completion date: May 2018

Study information

• Verified date: June 2015
• Source: National University Hospital, Singapore
• Contact: Wei Peng Yong, MRCP
• Phone: +65 6779 5555
• Email: wei_peng_yong[@]nuhs.edu.sg
• Is FDA regulated: No
• Health authority: Singapore: Domain Specific Review Boards
• Study type: Observational

Clinical Trial Summary

Peripheral blood will be taken from the enrolled patients at National University Hospital and from healthy volunteers. ADCC assay will be performed for evaluating efficacy of new medicine candidates.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: May 2018
• Est. primary completion date: May 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years to 80 Years

Eligibility

Inclusion Criteria:

For the gastric cancer patients, patients with 21 years of age and above and younger than 80 years old who have gastric cancer can enroll in this study. For the healthy donors, healthy volunteers with 21 years of age and above and younger than 80 years old can enroll in this study.

Exclusion Criteria:

(A) Age of <21 and >80 years old (B) Pregnancy (C) Decision of unsuitableness by Principal Investigator or physician-in-charge

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Locations

Country	Name	City	State
Singapore	National University Hospital	Singapore

Sponsors (1)

Lead Sponsor	Collaborator
National University Hospital, Singapore

Country where clinical trial is conducted

Singapore, 

References & Publications (1)

Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 Sep 6;345(10):725-30. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of cell lysis		within 1 year	No